Cold Agglutinin Disease is a very, rare, immune mediated condition, in which components of blood agglutinate in the vessels, causing thrombus formation with subsequent loss of blood supply.
In addition, Apellis and SFJ have entered into a letter of intent to negotiate and enter into a joint development agreement to support Apellis' clinical development programs for APL-2 for the treatment of patients with
cold agglutinin disease and warm antibody hemolytic anemia.
The author mentioned the treatment methods recommended for
cold agglutinin disease, which is a type of autoimmune hemolytic anemia (AIHA).
Idiotypic/antiidiotypic interactions are suggested to suppress tissue damage caused by autoantibodies in a number of conditions including autoimmune thyroiditis, SLE, pernicious anemia,
cold agglutinin disease, myasthenia gravis, and idiopathic thrombocytopenic purpura.